Journal article
Improvement of cognitive function in schizophrenia with N-acetylcysteine: A theoretical review
COB Yolland, A Phillipou, DJ Castle, E Neill, ME Hughes, C Galletly, ZM Smith, PS Francis, OM Dean, J Sarris, D Siskind, AWF Harris, SL Rossell
Nutritional Neuroscience | TAYLOR & FRANCIS LTD | Published : 2020
Abstract
Objectives: Schizophrenia is a debilitating psychiatric illness associated with positive and negative symptoms as well as significant impairments in cognition. Current antipsychotic medications do not alleviate these cognitive deficits, and more effective therapeutic options are required. Increased oxidative stress and altered antioxidant levels, including glutathione (GSH) have been observed both in individuals with cognitive impairment and in people with schizophrenia. A GSH precursor, the antioxidant N-acetylcysteine (NAC) has been investigated as a novel treatment for the cognitive symptoms of schizophrenia, and recent research suggests that NAC may be a promising adjunctive treatment op..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
This work was supported by National Health and Medical Research Council (AU) [Grant Number 1098442]. JS is supported by an NHMRC Clinical Research Fellowship [APP1125000].